We used a combination of radioiodine scanning and quantitative radiation dosimetry to evaluate responses to therapeutic irradiation with 131I in 76 patients with thyroid adenocarcinoma. Fifty patients received 131I treatment for ablation of residual thyroid tissue after surgical thyroidectomy, and 26 had 131I treatment for metastatic thyroid cancer. Successful ablation was observed in patients receiving higher radiation doses to the thyroid--about 4.4 times those in patients whose lesions were not ablated--largely because of a longer effective half-life of 131I in residual thyroid tissue in the patients with ablated lesions. Patients with metastases that persisted after 131I therapy tended to have more advanced disease and received significantly lower radiation doses per millicurie of administered 131I than did persons whose lesions responded to treatment. Initial 131I treatment resulting in radiation doses of at least 30,000 rad to thyroid remnants and 8000 rad to metastases was associated with a significant increase in the rate of response to therapy.
This article has been cited by other articles:
Lassmann, M., Hanscheid, H.
(2007). Spatial Dose Mapping for Individualizing Radioiodine Treatment. JNM
48: 2-4
[Full Text]
Mazzaferri, E. L.
(2005). Empirically Treating High Serum Thyroglobulin Levels. JNM
46: 1079-1088
[Full Text]
Robbins, R. J., Schlumberger, M. J.
(2005). The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma. JNM
46: 28S-37S
[Abstract][Full Text]
Sgouros, G., Kolbert, K. S., Sheikh, A., Pentlow, K. S., Mun, E. F., Barth, A., Robbins, R. J., Larson, S. M.
(2004). Patient-Specific Dosimetry for 131I Thyroid Cancer Therapy Using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) Software. JNM
45: 1366-1372
[Abstract][Full Text]
Furuya, F., Shimura, H., Suzuki, H., Taki, K., Ohta, K., Haraguchi, K., Onaya, T., Endo, T., Kobayashi, T.
(2004). Histone Deacetylase Inhibitors Restore Radioiodide Uptake and Retention in Poorly Differentiated and Anaplastic Thyroid Cancer Cells by Expression of the Sodium/Iodide Symporter Thyroperoxidase and Thyroglobulin. Endocrinology
145: 2865-2875
[Abstract][Full Text]
Haberkorn, U., Beuter, P., Kubler, W., Eskerski, H., Eisenhut, M., Kinscherf, R., Zitzmann, S., Strauss, L. G., Dimitrakopoulou-Strauss, A., Altmann, A.
(2004). Iodide Kinetics and Dosimetry In Vivo After Transfer of the Human Sodium Iodide Symporter Gene in Rat Thyroid Carcinoma Cells. JNM
45: 827-833
[Abstract][Full Text]
Robbins, R. J., Pentlow, K. S.
(2003). Coming of Age: Recombinant Human Thyroid-Stimulating Hormone as a Preparation for 131I Therapy in Thyroid Cancer. JNM
44: 1069-1071
[Full Text]
Parthasarathy, K. L., Crawford, E. S.
(2002). Treatment of Thyroid Carcinoma: Emphasis on High-Dose 131I Outpatient Therapy. J. Nucl. Med. Technol.
30: 165-171
[Abstract][Full Text]
Pacini, F., Molinaro, E., Castagna, M. G., Lippi, F., Ceccarelli, C., Agate, L., Elisei, R., Pinchera, A.
(2002). Ablation of Thyroid Residues with 30 mCi 131I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal. J. Clin. Endocrinol. Metab.
87: 4063-4068
[Abstract][Full Text]
Smit, J. W. A., Schroder-van der Elst, J. P., Karperien, M., Que, I., Stokkel, M., van der Heide, D., Romijn, J. A.
(2002). Iodide Kinetics and Experimental 131I Therapy in a Xenotransplanted Human Sodium-Iodide Symporter-Transfected Human Follicular Thyroid Carcinoma Cell Line. J. Clin. Endocrinol. Metab.
87: 1247-1253
[Abstract][Full Text]
Clarke, S E M
(2001). Advances in radionuclide imaging: radionuclide imaging as a guide to therapy. Imaging
13: 171-184
[Abstract][Full Text]
Morris, L. F., Waxman, A. D., Braunstein, G. D.
(2001). The Nonimpact of Thyroid Stunning: Remnant Ablation Rates in 131I-Scanned and Nonscanned Individuals. J. Clin. Endocrinol. Metab.
86: 3507-3511
[Abstract][Full Text]
Mazzaferri, E. L., Kloos, R. T.
(2001). Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer. J. Clin. Endocrinol. Metab.
86: 1447-1463
[Full Text]
Nakamoto, Y., Saga, T., Misaki, T., Kobayashi, H., Sato, N., Ishimori, T., Kosugi, S., Sakahara, H., Konishi, J.
(2000). Establishment and Characterization of a Breast Cancer Cell Line Expressing Na+/I- Symporters for Radioiodide Concentrator Gene Therapy. JNM
41: 1898-1904
[Abstract][Full Text]
Boland, A., Ricard, M., Opolon, P., Bidart, J.-M., Yeh, P., Filetti, S., Schlumberger, M., Perricaudet, M.
(2000). Adenovirus-mediated Transfer of the Thyroid Sodium/Iodide Symporter Gene into Tumors for a Targeted Radiotherapy. Cancer Res.
60: 3484-3492
[Abstract][Full Text]
Rotman-Pikielny, P., Reynolds, J. C., Barker, W. C., Yen, P. M., Skarulis, M. C., Sarlis, N. J.
(2000). Recombinant Human Thyrotropin for the Diagnosis and Treatment of a Highly Functional Metastatic Struma Ovarii. J. Clin. Endocrinol. Metab.
85: 237-244
[Abstract][Full Text]
Koong, S.-S., Reynolds, J. C., Movius, E. G., Keenan, A. M., Ain, K. B., Lakshmanan, M. C., Robbins, J.
(1999). Lithium as a Potential Adjuvant to 131I Therapy of Metastatic, Well Differentiated Thyroid Carcinoma. J. Clin. Endocrinol. Metab.
84: 912-916
[Abstract][Full Text]
Rivkees, S. A., Sklar, C., Freemark, M.
(1998). The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment. J. Clin. Endocrinol. Metab.
83: 3767-3776
[Full Text]
Travagli, J. P., Cailleux, A. F., Ricard, M., Baudin, E., Caillou, B., Parmentier, C., Schlumberger, M.
(1998). Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma. J. Clin. Endocrinol. Metab.
83: 2675-2680
[Abstract][Full Text]
Schlumberger, M. J.
(1998). Papillary and Follicular Thyroid Carcinoma. NEJM
338: 297-306
[Full Text]
